vimarsana.com

Page 6 - அமைப்புகள் மருந்தியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Antibodies to common cold coronaviruses do not protect against SARS-CoV-2

 E-Mail PHILADELPHIA Past exposure to seasonal coronaviruses (CoVs), which cause the common cold, does not result in the production of antibodies that protect against the novel coronavirus SARS-CoV-2, according to a study led by Scott Hensley, PhD, an associate professor of Microbiology at the Perelman School of Medicine at the University of Pennsylvania. Prior studies have suggested that recent exposure to seasonal CoVs protects against SARS-CoV-2, the virus that causes COVID-19. However, research from Hensley s team, published in Cell, suggests that if there is such protection, it does not come from antibodies. We found that many people possessed antibodies that could bind to SARS-CoV-2 before the pandemic, but these antibodies could not prevent infections, Hensley said. Although antibodies from prior coronavirus infections cannot prevent SARS-CoV-2 infections, it is possible that pre-existing memory B cells and T cells could potentially provide some level of protection

Synthekine Strengthens Leadership with Board of Directors Expansion and Scientific Advisory Board Formation

Published: Feb 04, 2021     MENLO PARK, Calif. (BUSINESS WIRE) Synthekine Inc., an engineered cytokine therapeutics company, today announced that it has appointed Pablo Cagnoni, M.D., to its board of directors. Dr. Cagnoni brings to Synthekine extensive leadership experience in the biotech industry and a successful track record of oncology drug development. The company also announced the formation of its scientific advisory board to help guide the company’s extensive cytokine engineering efforts. “Synthekine has made significant advances in 2020, with our first programs on track for IND filings in 2021, and I am delighted to have Pablo join our board of directors and bring his considerable insights in developing breakthrough oncology products to support our continued progress,” said Debanjan Ray, CEO of Synthekine. “At the same time, our distinguished scientific advisory board will provide guidance as we apply our multiple cytokine engineering efforts to importan

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.